- Home
- JAZZ vs ACI Comparison
JAZZ vs ACI Comparison
Compare JAZZ & ACI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAZZ
- ACI
- Stock Information
- Founded
- JAZZ 2003
- ACI 1860
- Country
- JAZZ Ireland
- ACI United States
- Employees
- JAZZ N/A
- ACI N/A
- Industry
- JAZZ Biotechnology: Pharmaceutical Preparations
- ACI Food Chains
- Sector
- JAZZ Health Care
- ACI Consumer Staples
- Exchange
- JAZZ Nasdaq
- ACI Nasdaq
- Market Cap
- JAZZ 8.2B
- ACI 9.6B
- IPO Year
- JAZZ 2007
- ACI 2020
- Fundamental
- Price
- JAZZ $141.45
- ACI $18.01
- Analyst Decision
- JAZZ Strong Buy
- ACI Buy
- Analyst Count
- JAZZ 14
- ACI 14
- Target Price
- JAZZ $179.71
- ACI $24.14
- AVG Volume (30 Days)
- JAZZ 739.6K
- ACI 8.0M
- Earning Date
- JAZZ 11-05-2025
- ACI 10-14-2025
- Dividend Yield
- JAZZ N/A
- ACI 3.34%
- EPS Growth
- JAZZ N/A
- ACI N/A
- EPS
- JAZZ N/A
- ACI 1.69
- Revenue
- JAZZ $4,157,832,999.00
- ACI $81,370,600,000.00
- Revenue This Year
- JAZZ $5.80
- ACI $4.87
- Revenue Next Year
- JAZZ $6.06
- ACI $0.54
- P/E Ratio
- JAZZ N/A
- ACI $10.61
- Revenue Growth
- JAZZ 4.14
- ACI 2.08
- 52 Week Low
- JAZZ $95.49
- ACI $16.70
- 52 Week High
- JAZZ $148.06
- ACI $23.20
- Technical
- Relative Strength Index (RSI)
- JAZZ 61.16
- ACI 48.76
- Support Level
- JAZZ $128.80
- ACI $17.38
- Resistance Level
- JAZZ $144.97
- ACI $17.92
- Average True Range (ATR)
- JAZZ 4.65
- ACI 0.39
- MACD
- JAZZ -0.13
- ACI -0.03
- Stochastic Oscillator
- JAZZ 75.14
- ACI 50.74
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About ACI Albertsons Companies Inc.
Albertsons is the second-largest supermarket operator in the United States with about 2,300 stores across a variety of banners. Around 80% of the firm's sales comes from nonperishable and fresh food, of which 26% comes from its portfolio of private brands. The company operates fuel centers at about 20% of its store locations and pharmacies at 75%. Albertsons went public in 2020 following years of ownership under private equity firm Cerberus Capital Management, which still owns about a fourth of the outstanding shares.